Taken together, these observations support the opinion that SGLT2 inhibitors may reduce LV mass by targeting both EAT and overall body weight, highlighting their potential to improve cardiac structure and function in patients with heart failure and type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.